Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock
Primary Purpose
Cirrhosis
Status
Withdrawn
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Liberal
Restrictive
Sponsored by
About this trial
This is an interventional treatment trial for Cirrhosis
Eligibility Criteria
Inclusion Criteria:
- Cirrhosis with septic shock.
- Age >18 years
Exclusion Criteria:
- Previous severe adverse reaction with blood products,
- Disseminated intravascular coagulopathy
- HCC
- Pregnancy
- Malignancy
- Active gastrointestinal bleeding
- Intracranial bleeding
- Chronic Kidney disease with Maintenance Hemodialysis
- Pulmonary Edema
- Congestive Heart Failure
- Lack of informed consent
Sites / Locations
- Institute of Liver and Biliary Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Liberal
Restrictive
Arm Description
2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
To maintain the target Hemoglobin of 7 to 8 gm/dL.
Outcomes
Primary Outcome Measures
Mortality in both groups
Secondary Outcome Measures
Improvement in vasopressors in both groups
Improvement is defined as tapering the dose of vasopressors
Incidence of complications in both groups
Length of ICU (Intensive Care Unit) stay
Requirement of mechanical ventilation in both groups
Full Information
NCT ID
NCT03433508
First Posted
February 8, 2018
Last Updated
November 1, 2019
Sponsor
Institute of Liver and Biliary Sciences, India
1. Study Identification
Unique Protocol Identification Number
NCT03433508
Brief Title
Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock
Official Title
Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock: An Open Label Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Withdrawn
Why Stopped
lack of funds
Study Start Date
December 15, 2018 (Anticipated)
Primary Completion Date
February 15, 2019 (Anticipated)
Study Completion Date
February 15, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Liver and Biliary Sciences, India
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Consecutive cirrhotics who present to emergency department of ILBS with documented or suspected sepsis induced hypotension with Hb <8 gm/dl will be randomly assigned to restrictive (Target Hb 7-8 gm/dl) to liberal (Target Hb 10-11 gm/dl) group in a 1:1 proportion At admission, all patients will undergo physical examination and baseline investigations to identify site of sepsis. Enrolled patients will be given PRBC-transfusion (Not more than two units of PRBC/day) when they reach their assigned trigger value (Hb 7-8 g/dl or 10-11 g/dl ) during the entire ICU stay. All other interventions will be at the discretion of clinicians.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cirrhosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Liberal
Arm Type
Experimental
Arm Description
2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
Arm Title
Restrictive
Arm Type
Active Comparator
Arm Description
To maintain the target Hemoglobin of 7 to 8 gm/dL.
Intervention Type
Biological
Intervention Name(s)
Liberal
Intervention Description
2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
Intervention Type
Other
Intervention Name(s)
Restrictive
Intervention Description
To maintain the target Hemoglobin of 7 to 8 gm/dL.
Primary Outcome Measure Information:
Title
Mortality in both groups
Time Frame
28 dyas
Secondary Outcome Measure Information:
Title
Improvement in vasopressors in both groups
Description
Improvement is defined as tapering the dose of vasopressors
Time Frame
28 days
Title
Incidence of complications in both groups
Time Frame
28 days
Title
Length of ICU (Intensive Care Unit) stay
Time Frame
28 days
Title
Requirement of mechanical ventilation in both groups
Time Frame
28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Cirrhosis with septic shock.
Age >18 years
Exclusion Criteria:
Previous severe adverse reaction with blood products,
Disseminated intravascular coagulopathy
HCC
Pregnancy
Malignancy
Active gastrointestinal bleeding
Intracranial bleeding
Chronic Kidney disease with Maintenance Hemodialysis
Pulmonary Edema
Congestive Heart Failure
Lack of informed consent
Facility Information:
Facility Name
Institute of Liver and Biliary Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110070
Country
India
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock
We'll reach out to this number within 24 hrs